Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roche Presents New OCREVUS And Fenebrutinib Data At ECTRIMS 2025 Showing Long-Term Benefits Across Broad Multiple Sclerosis Populations

Author: Benzinga Newsdesk | September 24, 2025 02:41am
  • OCREVUS subcutaneous maintains consistent benefit-risk profile after two years
  • New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMS
  • One-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responses
  • Fenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeks

Posted In: RHHBF RHHBY RHHVF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist